Table 1.
Background and SARS-CoV-2 antibody titers of the control and NMDs groups.
| Variables | Control group | NMDs group | p value |
|---|---|---|---|
| N | 346 | 11 (SMA, 9; DMD, 2) | |
| Sex (male:female) | 60:286 | 7:4 | 0.001 |
| Age (years) | 40.0 ± 12.4 | 32.7 ± 19.3 | 0.062 |
| SARS-CoV-2 antibody titers (U/mL) | |||
| Before vaccination | <0.40 | <0.40 | 1.000 |
| Two weeks after first vaccination | 103 ± 1192 | 145 ± 258 | 0.909 |
| Male | 26 ± 29 | 203 ± 312 | <0.001 |
| Female | 42 ± 69 | 42 ± 70 | 0.998 |
| Two weeks after second vaccination | 1429 ± 944 | 1528 ± 1265 | 0.736 |
| Male | 1167 ± 633 | 1206 ±990 | 0.886 |
| Female | 1486 ± 991* | 2091 ±1646 | 0.230 |
DMD: Duchenne muscular dystrophy; NMDs: neuromuscular disorders; SMA: spinal muscular atrophy; *, In the control group, females had significantly higher antibody titers than males after the second vaccination (p = 0.0176).